{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xie X"],"funding":["NIH/NCI","NCI NIH HHS","State of Texas Rare and Aggressive Breast Cancer Research Program","Morgan Welch Inflammatory Breast Cancer Research Program","NIH HHS"],"pagination":["735"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10045293"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(3)"],"pubmed_abstract":["Background
Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is approved by the U.S. Food and Drug Administration to treat metastatic breast cancer after at least two previous chemotherapeutic regimens. However, eribulin as a single agent has limited therapeutic efficacy against TNBC.Methods
High-throughput kinome library RNAi screening, Ingenuity Pathway Analysis, and STRING analysis were performed to identify target kinases for combination with eribulin. The identified combinations were validated using i"],"journal":["Biomedicines"],"pubmed_title":["Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines."],"pmcid":["PMC10045293"],"funding_grant_id":["P30CA016672","P30 CA016672","P30 CA054174"],"pubmed_authors":["Liu H","Yun K","Fuson JA","Xie X","Lee J","Margain C","Ueno NT","Tripathy D","Iwase T"],"additional_accession":[]},"is_claimable":false,"name":"Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.","description":"Background
Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is approved by the U.S. Food and Drug Administration to treat metastatic breast cancer after at least two previous chemotherapeutic regimens. However, eribulin as a single agent has limited therapeutic efficacy against TNBC.Methods
High-throughput kinome library RNAi screening, Ingenuity Pathway Analysis, and STRING analysis were performed to identify target kinases for combination with eribulin. The identified combinations were validated using i","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-04-08T14:15:38.945Z","creation":"2025-02-19T02:38:17.809Z"},"accession":"S-EPMC10045293","cross_references":{"pubmed":["36979714"],"doi":["10.3390/biomedicines11030735"]}}